Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.07M Buy
1,552,904
+492,446
+46% +$478K ﹤0.01% 5500
2025
Q4
$1.07M Buy
1,060,458
+819,280
+340% +$1.16M ﹤0.01% 5503
2025
Q3
$309K Buy
241,178
+103,573
+75% +$135K ﹤0.01% 6421
2025
Q2
$139K Buy
+137,605
New +$158K ﹤0.01% 6974
2025
Q1
Sell
-126,200
Closed -$227K 10568
2024
Q4
$227K Buy
126,200
+124,215
+6,258% +$241K ﹤0.01% 6376
2024
Q3
$3.65K Buy
1,985
+1,815
+1,068% +$3.02K ﹤0.01% 8239
2024
Q2
$304 Sell
170
-4,381
-96% -$9.79K ﹤0.01% 8989
2024
Q1
$10.2K Buy
4,551
+3,959
+669% +$7.99K ﹤0.01% 7242
2023
Q4
$1.15K Buy
+592
New +$1.11K ﹤0.01% 8393
2023
Q2
Sell
-6,898
Closed -$24.8K 9418
2023
Q1
$24.8K Buy
6,898
+6,798
+6,798% +$29.8K ﹤0.01% 6919
2022
Q4
$410 Hold
100
﹤0.01% 10198
2022
Q3
$0 Hold
100
﹤0.01% 10737
2022
Q2
$1K Buy
+100
New +$1.24K ﹤0.01% 9924

Other funds holding NVX

UBS Group's NVX Position: Q1 2026 in Review

UBS Group increased its NOVONIX (NVX) stake by 46% in Q1 2026, buying an estimated $478K and bringing the position to 1,552,904 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #5500.

UBS Group first reported a position in NVX in Q2 2022 and has held it in 13 quarters since. 32 funds tracked by Wall St. Rank hold NVX as of Q1 2026.

  • UBS Group held 1,552,904 shares of NOVONIX worth $1.07M as of Q1 2026.
  • UBS Group bought 492,446 NOVONIX shares in Q1 2026, an estimated $478K.
  • NOVONIX made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5500 holding.
  • UBS Group first reported a position in NOVONIX in Q2 2022 and has held it in 13 quarters since.
  • 32 funds tracked by Wall St. Rank held NOVONIX as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.